Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.
2.

Assessment of indirect hemagglutination and zymography procedures in evaluation of gelatinase a in patients with benign and malignant prostate hyperplasia.

Aalizadeh N, Pezeshki M, Korramizadeh MR, Eslami MB, Zeraati H.

Iran J Allergy Asthma Immunol. 2003 Sep;2(3):159-63.

3.

Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.

Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, Egawa S, Baba S.

Anticancer Res. 2002 May-Jun;22(3):1813-7.

PMID:
12168874
4.

Is there a role for serum human tissue kallikrein in detection of prostate cancer?

Ochiai A, Shukla A, Davis JW, Fritsche HA, Bhadkamkar V, Babaian RJ.

Urology. 2007 Sep;70(3):519-22.

PMID:
17905108
5.
7.

The variation of percent free prostate-specific antigen determined by two different assays.

Yang CR, Ou YC, Horng YY, Lee HS.

Anticancer Res. 2003 Jan-Feb;23(1B):707-11.

PMID:
12680171
8.

Multigene methylation analysis for detection and staging of prostate cancer.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

9.

Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.

Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.

Cancer. 2008 Nov 15;113(10):2695-703. doi: 10.1002/cncr.23885.

10.

Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.

Sarrats A, Comet J, Tabarés G, Ramírez M, Aleixandre RN, de Llorens R, Peracaula R.

Prostate. 2010 Jan 1;70(1):1-9. doi: 10.1002/pros.21031.

PMID:
19670261
11.
12.

[Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].

Song G, Zhou LQ, He ZS, Li NC, Li M, Hao JR, Pan BN, Na YQ.

Zhonghua Wai Ke Za Zhi. 2006 Mar 15;44(6):376-8. Chinese.

PMID:
16638345
13.
14.

IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.

Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.

Eur Urol. 2006 Feb;49(2):286-92; discussion 292. Epub 2005 Dec 7.

PMID:
16386354
15.

Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL.

Eskicorapci SY, Ozkara HA, Onder E, Akdogan B, Erkan I, Ciliv G, Ozen H.

Clin Biochem. 2006 Apr;39(4):363-6. Epub 2006 Jan 19.

PMID:
16423339
16.

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.

Urology. 2006 Aug;68(2):342-7.

PMID:
16904449
17.

The chromogranin-A (CgA) in prostate cancer.

Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M.

Arch Gerontol Geriatr. 2006 Jul-Aug;43(1):117-26. Epub 2005 Nov 8.

PMID:
16280180
18.

[Value of prostate specific antigen in early diagnosis of prostatic cancer].

Xiao LP, Bi XJ, Li YN, Chen XQ, Zhang XF, Yu XP, Liu G, Yang MC, Song Z.

Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jan;27(1):107-8, 112. Chinese.

PMID:
17259162
20.

[Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].

Sun CC, Zheng W, Kong CZ, Wang X, Yang CM.

Zhonghua Nan Ke Xue. 2006 Oct;12(10):904-5, 909. Chinese.

PMID:
17121020

Supplemental Content

Support Center